Trial reportEuropean journal of clinical pharmacology2015
Dexmedetomidine pharmacokinetics in the obese.
Trial report in European journal of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 64 citations in OpenAlex.
- Levobupivacaine absorption pharmacokinetics with and without epinephrine during TAP block: analysis of doses based on the associated risk of local anaesthetic toxicity.European journal of clinical pharmacology · 2016Trial
- Dexmedetomidine for Conscious Sedation and Controlled Hypotension in Head and Neck Surgery: A Single-Centre Experience.Medicina (Kaunas, Lithuania) · 2026Observational
- Dexmedetomidine attenuates high-fat diet-induced metabolic dysfunction-associated steatotic liver disease in rats by regulating the autophagic pathway.Scientific reports · 2026Article
- Dexmedetomidine's Role in Adult ICU After 20 Years of Experience-A Narrative Review.Healthcare (Basel, Switzerland) · 2025Review
- Article
- Population Pharmacokinetics of IV Lidocaine and its Metabolites in Adult Surgical Patients.Pharmaceutical research · 2025Article
- Reinforcement learning model for optimizing dexmedetomidine dosing to prevent delirium in critically ill patients.NPJ digital medicine · 2024Article
- Using Real-World Data to Externally Evaluate Population Pharmacokinetic Models of Dexmedetomidine in Children and Infants.Journal of clinical pharmacology · 2024Article
- Predictors for Dexmedetomidine Requirement for Sedation under Regional Anesthesia.Journal of clinical medicine · 2024Article
- Perioperative Acetaminophen Dosing in Obese Children.Children (Basel, Switzerland) · 2023Review
- Justification Of Empiric Methodology to Determine Dexmedetomidine Dose for the TREX Study.Paediatric anaesthesia · 2023Article
- Considerations for Intravenous Anesthesia Dose in Obese Children: Understanding PKPD.Journal of clinical medicine · 2023Review
- EEG response of dexmedetomidine during drug induced sleep endoscopy.Frontiers in neuroscience · 2023Article
- Population Pharmacokinetic Modelling of Acetaminophen and Ibuprofen: the Influence of Body Composition, Formulation and Feeding in Healthy Adult Volunteers.European journal of drug metabolism and pharmacokinetics · 2022Article
- Pharmacokinetic Pharmacodynamic Modelling Contributions to Improve Paediatric Anaesthesia Practice.Journal of clinical medicine · 2022Review
- General Purpose Pharmacokinetic-Pharmacodynamic Models for Target-Controlled Infusion of Anaesthetic Drugs: A Narrative Review.Journal of clinical medicine · 2022Review
- CYP2A6 and GABRA2 Gene Polymorphisms are Associated With Dexmedetomidine Drug Response.Frontiers in pharmacology · 2022Article
- Dexmedetomidine-induced hemodynamic instability in patients undergoing orthopedic upper limb surgery under brachial plexus block: a retrospective study.BMC anesthesiology · 2021Article
- Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies.European journal of clinical pharmacology · 2021Article
- A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to characterize the influence of body weight and composition on the pharmacokinetics of dexmedetomidine.
methodsTwenty obese patients and 20 non-obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine infusion schemes. Venous blood samples were taken during and after dexmedetomidine administration. Population pharmacokinetic modeling was undertaken to investigate fat free mass (FFM) and normal fat mass (NFM) as size descriptors of volumes and clearances using non-linear mixed effects modeling. NFM partitions total body weight into FFM and fat mass calculated from total body weight (TBW) minus FFM. The relative influence of fat mass compared to FFM is described by the fraction of fat mass that makes fat equivalent to FFM (Ffat).
resultsTheory-based allometric scaling using FFM best described weight and body composition differences in clearances and volumes A negative effect of fat mass of with an exponential parameter of -0.00541/kg (95 % CI -0.0118 to -0.00246) was estimated for clearance which indicates increased fat mass is associated with impairment of clearance.
conclusionsThe use of theory-based allometry with predictions of fat free mass has been able to separate the influences of weight and body composition and indicates that size-normalized clearance of dexmedetomidine is impaired in patients who are obese.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.